Trials / Withdrawn
WithdrawnNCT03904069
Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML
A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 Chimeric Antigen Receptor T-cell (CAR-T) AMG 553 in Subjects With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia.
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety and tolerability of AMG 553 in adult and adolescent subjects with FLT3-positive R/R AML. Determine the maximum tolerated cell dose (MTCD) or recommended phase 2 cell dose (RP2CD) of AMG 553.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 553 | AMG 553 is a chimeric antigen T-cell receptor (CAR-T) therapy |
Timeline
- Start date
- 2023-03-13
- Primary completion
- 2030-08-07
- Completion
- 2030-08-07
- First posted
- 2019-04-04
- Last updated
- 2023-06-12
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03904069. Inclusion in this directory is not an endorsement.